We're buying the dip in our newest chip stock, getting a better price on a great name

Jim Cramer's Charitable Trust is buying 100 more Intel shares at roughly $103, lifting its position to 500 shares and portfolio weight to 1.3% from 1.06%. The commentary is constructive on Intel's CPU business for the Agentic AI era and on CEO Lip-Bu Tan's execution improvements, while also citing potential upside in foundry/advanced packaging. Near-term stock action remains tied to the semiconductor selloff, with Intel down 8% on the day and about 20% below its May 11 closing high of just over $129.

Analysis

The important read-through is not simply that Intel is cheapened by a selloff; it is that the market is still pricing INTC like a single-bet, legacy CPU turnaround, while the optionality increasingly comes from its role as a capacity-constrained alternative in the advanced packaging/foundry ecosystem. If management keeps execution steady, the equity can rerate on a mix shift: less skepticism on core server share stability and more willingness to assign value to manufacturing optionality that is currently largely unpriced. That creates a convex setup where even modest operational wins can matter disproportionately over the next 6-12 months.

Second-order beneficiaries are the suppliers and ecosystem names that gain if Intel’s manufacturing ambitions pull in external customers. The real constraint is not demand for an alternative to Taiwan Semi, but confidence: customers need evidence that Intel can deliver yields, packaging consistency, and schedule reliability over multiple nodes, not just one headline win. Until that proof point arrives, the stock remains vulnerable to every macro semiconductor risk-off tape, but the downside should be less severe if the CPU narrative and foundry narrative start reinforcing each other.

The contrarian view is that the market may be underestimating how fast AI infrastructure architecture can normalize CPU demand alongside GPUs, which would make the current debate too narrowly centered on accelerators. The flip side is timing: foundry upside is a multi-quarter story, while the stock can still trade like a high-beta semiconductor in days-to-weeks tape shocks. That means the risk/reward is better framed as a staged position with clear add levels rather than an all-in buy, because the catalyst path is operational, not purely sentiment-driven.

Key Decisions for Investors

• Add to INTC on weakness over the next 1-3 weeks; use a staged entry rather than full size, because the thesis improves over 6-12 months while tape risk remains high in the near term.
• Pair trade: long INTC / short NVDA into semiconductor selloffs when AI infrastructure risk comes off, targeting relative outperformance if the market starts rewarding CPU-to-GPU balance rather than only accelerator exposure.
• Buy INTC call spreads 3-6 months out to express upside convexity from execution improvement; structure for limited downside and participation if the market begins to assign foundry optionality value.
• If INTC reclaims prior breakdown levels and holds for several sessions, add to the long; if it fails on broad tech strength, trim because that would signal the market is still treating it as a value trap rather than a credible turnaround.